Jun 17, 2020
Candela Announces Health Canada Approval Of Two New Gynecological Indications For CO2RE® Laser Platform
Jun 04, 2020
Duchesnay USA and FabOverFifty launch Straight Talk: Sex and the Menopausal Woman video
Nov 13, 2019
Vaginal Rejuvenation Market Worth $11.8 Billion By 2026 | CAGR: 12.5%: Grand View Research, Inc.
Nov 06, 2019
Endoceutics® Receives Health Canada Approval for INTRAROSA®
Aug 27, 2019
Health Canada Clears Fotona Dynamis for Stress Urinary Incontinence (SUI) and Vulvovaginal Atrophy (VVA) / Genitourinary Syndrome of Menopause (GSM)
Feb 14, 2019
diVa By Sciton Receives Approved Indication For The Treatment Of Genitourinary Symptoms Of Menopause (GSM) By Health Canada
Oct 29, 2018
Duchesnay USA, Maker of Osphena®, Applauds Expanded Coverage for Treatments for Dyspareunia due to Menopause under Medicare Part D
Oct 23, 2018
Duchesnay Inc. Announces Submission of Supplemental New Drug Application (sNDA) for Osphena® (ospemifene) to U.S. FDA Seeking Approval for the Treatment of Vaginal Dryness, a Symptom of Vulvar and Vaginal Atrophy (VVA) Due to Menopause
Aug 09, 2018
New Study on Vulvovaginal Atrophy (VVA) Concludes that VVA Needs More Attention and Intervention by Providers
Jul 19, 2018
Theramex to Exclusively License Intrarosa® In Europe, Australia, Russia and The Ukraine from Endoceutics
Jun 23, 2018
Dr. John R. Burroughs of Springs Aesthetics Now Offering vFit PLUS Feminine Wellness Treatment Device
Jun 06, 2018
Thermi's Temperature-Controlled Radiofrequency System Improved Common Vaginal Disorders And Sexual Function, Published Study Shows
May 30, 2018
TherapeuticsMD Announces FDA Approval of TX-004HR: IMVEXXY(TM) (estradiol vaginal inserts), the Lowest Dose Vaginal Estrogen Product Approved for the Treatment of Moderate to Severe Dyspareunia, a Symptom of VVA, due to Menopause
May 10, 2018
Dyspareunia: CMS Clarification Results In Expanded Treatment And Coverage Under Medicare Part D
Apr 11, 2018
Alma Lasers Announces Presentation of 15 Abstracts at ASLMS 2018 38th Annual Conference.